Abstract: Pharmaceutical compositions comprising an antidiabetic agent as an active agent are provided. The present invention relates to pharmaceutical compositions comprising linagliptin or a pharmaceutically acceptable salt thereof as an active agent. The present invention also relates to process of preparation of pharmaceutical compositions comprising linagliptin or a pharmaceutically acceptable salt thereof. The present invention also relates to method of administering the compositions comprising linagliptin to a subject in need thereof.

Abstract: The present invention relates to a process for the preparation of pure Paliperidone Palmitate, which comprises: (a) providing a solution of Paliperidone Palmitate in an alcoholic solvent; (b) adding the alcoholic solution of Paliperidone palmitate to water or vice versa; and (c) isolating the product to obtain pure Paliperidone Palmitate.

Abstract: The present invention relates to a process for the preparation of pure Paliperidone Palmitate, which comprises: (a) providing a solution of Paliperidone Palmitate in an alcoholic solvent; (b) adding the alcoholic solution of Paliperidone palmitate to water or vice versa; and (c) isolating the product to obtain pure Paliperidone Palmitate.

Abstract: The present invention relates to stable oral composition comprising linaclotide or its pharmaceutically acceptable salts, complexes, polymorphs, hydrates, solvates, enantiomers or racemates, process of preparation thereof and methods of using the same.

Abstract: The present invention provides a process for the preparation of crystalline anhydrous compound of Formula (X), Further, the present invention relates to the use of compound of Formula (X) preparation of Raltegravir (I) or its pharmaceutically acceptable salt thereof.

Abstract: The present invention relates to nicotine or nicotine polacrilex lozenge compositions comprising nicotine or nicotine derivatives as an active agent and the process for preparation thereof. The present invention also relates to method of using nicotine or nicotine polacrilex lozenge compositions for reducing withdrawal symptoms or tobacco usage particularly nicotine craving, associated with quitting smoking.

Abstract: The present invention provides (R)-3-Amino-1-butanol (D)-tartarate (IIb); process for its preparation and its conversion to Dolutegravir. The present invention also provides an improved process for the preparation of Dolutegravir (I) or pharmaceutically acceptable salts wherein compound (XVI) is reacted with an optically active acid addition salt of (R)-3-amino-1-butanol (IIa).

Abstract: The present invention provides (R)-3-Amino-1-butanol (D)-tartarate (IIb); process for its preparation and its conversion to Dolutegravir. The present invention also provides an improved process for the preparation of Dolutegravir (I) or pharmaceutically acceptable salts wherein compound (XVI) is reacted with an optically active acid addition salt of (R)-3-amino-1-butanol (IIa).

Abstract: Pharmaceutical compositions comprising tadalafil or a pharmaceutically acceptable salt thereof are provided. The present invention also relates to a process for preparation of pharmaceutical compositions comprising tadalafil or a pharmaceutically acceptable salt thereof. The present invention also relates to method of administering the compositions comprising tadalafil in a subject in need thereof.

Abstract: Sterile formulation comprising glucocorticosteroids, process for the preparation of the sterile formulation and method of using the same are provided. The present invention also relates to sterile formulation comprising budesonide, process for the preparation of the sterile formulation and method of using the same.

Abstract: Pharmaceutical compositions comprising an antidiabetic agent as an active agent are provided. The present invention relates to pharmaceutical compositions comprising linagliptin or a pharmaceutically acceptable salt thereof as an active agent. The present invention also relates to process of preparation of pharmaceutical compositions comprising linagliptin or a pharmaceutically acceptable salt thereof. The present invention also relates to method of administering the compositions comprising linagliptin to a subject in need thereof.

Abstract: Stabilized pharmaceutical compositions comprising a thrombin inhibitor as an active agent(s), process of preparation and method of using the same are provided. The present invention also relates to stabilized pharmaceutical compositions comprising dabigatran etexilate, or pharmaceutically acceptable salts, esters, hydrates and solvates thereof, process of preparation and method of using the same.

Abstract: Pharmaceutical compositions comprising an atypical antipsychotic as an active agent, process of preparation thereof and method of using the same are provided. Particularly the present invention relates to pharmaceutical compositions comprising lurasidone, process of preparation thereof and method to treat various psychotic disorders such as schizophrenia, positive and negative symptoms of schizophrenia, memory or learning dysfunctions caused by schizophrenia, senile dementia, attention deficit/hyperactivity disorder (ADHD), central nervous system (CNS) disorder responsive to modulation of glutamate levels, major depressive episodes associated with bipolar I disorder and other associated CNS disorders.

Abstract: Pharmaceutical compositions of anti-viral compounds, process for preparation and method of using the same are provided. Particularly, the present invention relates to chemically stable pharmaceutical compositions of efavirenz, emtricitabine and tenofovir disoproxil fumarate with optionally one or more pharmaceutically acceptable excipients, process for preparation and method for the treatment or prevention of the symptoms or effects of an HIV infection in an infected patient.

Abstract: Stabilized pharmaceutical compositions comprising a S1P receptor modulator as an active agent(s), process of preparation and method of using the same are provided. The present invention also relates to stabilized pharmaceutical compositions comprising fingolimod, or pharmaceutically acceptable salts, esters, hydrates and solvates thereof, process of preparation and method of using the same.

Abstract: The present invention relates to a process for preparing sterile ophthalmic suspension of carbonic anhydrase inhibitor. More particularly, the present invention relates to a process for preparing sterile ophthalmic suspension of brinzolamide.

Abstract: The present invention relates to a process for the preparation of pure Valsartan (I) substantially free from impurities of formulae (Ia), (Ib), and (Ic), which comprises: (i) condensing 2-(4?-bromomethylphenyl)benzonitrile of formula (II) with L-valine methyl ester hydrochloride of formula (V) in the presence of a base in a solvent to produce N-[(2?-cyanobiphenyl-4-yl)methyl]-(L)-valine methyl ester of formula (VI); (ii) treating the compound VI of step (i) with acid followed by treating with base to produce pure compound VI substantially free from dimeric impurity of formula (Via); (iii) reacting the pure compound of formula (VI) with n-valeryl chloride in the presence of a base to produce pure N-valeryl-N-[(2?-cyanobiphenyl-4-yl)methyl]-(L)-valine methyl ester (VII) substantially free from alkene impurity of formula (Vila); (iv) reacting the compound of formula (VII) with trialkyltin chloride and a metal azide in a solvent at a reflux temperature to produce N-(1-oxopentyl)-N-[[2?-(2-tributyltintetrazol-5-yl

Abstract: The present invention relates to an improved process to prepare Rosuvastatin calcium of Formula (I), with good quality. Further, the present invention also relates to a crystalline polymorphic form of Rosuvastatin ethyl ester.

Abstract: The present invention relates to a process for the preparation of Solifenacin succinate by condensing a compound of formula (IVb) with (RS)-3-quinuclidinol, wherein, R represents methyl, ethyl, isopropyl; to produce a diastereomeric mixture of (1S)-3,4-dihydro-1-phenyl-2(1H)-isoquinolinecarboxylic acid (3RS)-1-azabicyclo[2.2.2]oct-3-yl ester, which is treated with succinic acid in a solvent or mixture of solvents to produce optically pure Solifenacin succinate, Formula (X).

Abstract: The present invention provides an improved process for the preparation of Dutasteride (I) which comprises: (i) reacting 4-aza-5?-androst-1-en-3-one-17?-carboxylic acid (VII), Formula VII with sulfonic acid anhydride (RSO2)2O in presence of base to produce an intermediate compound of Formula (XIII), wherein R represents C1-6 alkyl, C1-6 halo alkyl, C6-10 aryl, halo aryl; (ii) condensing compound of Formula (XIII) with 2,5-bis(trifluoromethyl)aniline (III), Formula (III) in the presence or absence of a base to produce Dutasteride (I).